| Jamie Clark, | |
|
211 Gibson St Nw, Leesburg, VA 20176-2115 | |
| (703) 737-7707 | |
| Not Available |
| Full Name | Jamie Clark |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 15 Years |
| Location | 211 Gibson St Nw, Leesburg, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851564348 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 2201001128 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Audiology And Hearing Aid Center Of Gainesville, Pllc | 0547269680 | 5 |
News Archive
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question.
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011.
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children's Research Hospital scientists led the study, results of which set the stage to expand the use of a patient's genetic make-up to tailor chemotherapy.
Emerging Healthcare Solutions, Inc. disclosed today that Stand-By Systems has favorably completed their US Government Central Contractor Registration and is now eligible to sell their breakthrough products to the federal government. EHSI has verified the federal eligibility as part of their due diligence related to an option with Stand-By Systems (SBS), owner of the FDA approved SBS 1615 catalytic oxygen generator and associated systems. The option agreement allows EHSI management to perform due diligence prior to finalizing a definitive agreement.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.
› Verified 1 days ago
| Provider Name | Audiology And Hearing Aid Center Of Gainesville, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1841387016 PECOS PAC ID: 0547269680 Enrollment ID: O20061219000010 |
News Archive
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question.
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011.
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children's Research Hospital scientists led the study, results of which set the stage to expand the use of a patient's genetic make-up to tailor chemotherapy.
Emerging Healthcare Solutions, Inc. disclosed today that Stand-By Systems has favorably completed their US Government Central Contractor Registration and is now eligible to sell their breakthrough products to the federal government. EHSI has verified the federal eligibility as part of their due diligence related to an option with Stand-By Systems (SBS), owner of the FDA approved SBS 1615 catalytic oxygen generator and associated systems. The option agreement allows EHSI management to perform due diligence prior to finalizing a definitive agreement.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.
› Verified 1 days ago
| Provider Name | Privia Medical Group Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1013042480 PECOS PAC ID: 4385682061 Enrollment ID: O20140603000011 |
News Archive
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question.
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011.
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children's Research Hospital scientists led the study, results of which set the stage to expand the use of a patient's genetic make-up to tailor chemotherapy.
Emerging Healthcare Solutions, Inc. disclosed today that Stand-By Systems has favorably completed their US Government Central Contractor Registration and is now eligible to sell their breakthrough products to the federal government. EHSI has verified the federal eligibility as part of their due diligence related to an option with Stand-By Systems (SBS), owner of the FDA approved SBS 1615 catalytic oxygen generator and associated systems. The option agreement allows EHSI management to perform due diligence prior to finalizing a definitive agreement.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.
› Verified 1 days ago
| Provider Name | James Madison University |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1356882690 PECOS PAC ID: 4880917475 Enrollment ID: O20171218000057 |
News Archive
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question.
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011.
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children's Research Hospital scientists led the study, results of which set the stage to expand the use of a patient's genetic make-up to tailor chemotherapy.
Emerging Healthcare Solutions, Inc. disclosed today that Stand-By Systems has favorably completed their US Government Central Contractor Registration and is now eligible to sell their breakthrough products to the federal government. EHSI has verified the federal eligibility as part of their due diligence related to an option with Stand-By Systems (SBS), owner of the FDA approved SBS 1615 catalytic oxygen generator and associated systems. The option agreement allows EHSI management to perform due diligence prior to finalizing a definitive agreement.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamie Clark, 211 Gibson St Nw, Leesburg, VA 20176-2115 Ph: (703) 737-7707 | Jamie Clark, 211 Gibson St Nw, Leesburg, VA 20176-2115 Ph: (703) 737-7707 |
News Archive
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question.
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011.
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children's Research Hospital scientists led the study, results of which set the stage to expand the use of a patient's genetic make-up to tailor chemotherapy.
Emerging Healthcare Solutions, Inc. disclosed today that Stand-By Systems has favorably completed their US Government Central Contractor Registration and is now eligible to sell their breakthrough products to the federal government. EHSI has verified the federal eligibility as part of their due diligence related to an option with Stand-By Systems (SBS), owner of the FDA approved SBS 1615 catalytic oxygen generator and associated systems. The option agreement allows EHSI management to perform due diligence prior to finalizing a definitive agreement.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.
› Verified 1 days ago
Sheridan Healthy Hearing Services, Inc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 44045 Riverside Pkwy, Leesburg, VA 20176 Phone: 703-858-6000 | |
Dr. Kendall Delorenzo, AU.D., CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 19450 Deerfield Ave Ste 400, Leesburg, VA 20176 Phone: 703-687-6001 | |
Hilary J. Crowley, PH.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 211 Gibson St Nw, Suite 202, Leesburg, VA 20176 Phone: 703-999-2574 | |
Dr. Sharon Wicker, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 29 Fairfax St Se, Leesburg, VA 20175 Phone: 703-777-6424 Fax: 703-777-6456 | |
Advanced Hearing Aids & Audiology, Llc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 29 Fairfax St Se, Leesburg, VA 20175 Phone: 703-777-6424 Fax: 703-777-6456 |